search
Back to results

Nipple Aspiration, Ductal Lavage, and Duct Endoscopy For Diagnostic Assessment in Women Undergoing Surgery for Breast Cancer

Primary Purpose

Breast Cancer

Status
Unknown status
Phase
Phase 2
Locations
United Kingdom
Study Type
Interventional
Intervention
cytogenetic analysis
proteomic profiling
cytology specimen collection procedure
immunohistochemistry staining method
laboratory biomarker analysis
breast duct lavage
Sponsored by
Royal Marsden NHS Foundation Trust
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Breast Cancer focused on measuring stage II breast cancer, stage IIIA breast cancer, stage IIIB breast cancer, stage IIIC breast cancer, stage IA breast cancer, stage IB breast cancer

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleDoes not accept healthy volunteers

DISEASE CHARACTERISTICS: Diagnosis of breast cancer No metastatic disease No inflammatory breast cancer Hormone receptor status: Not specified PATIENT CHARACTERISTICS: Age 18 and over Sex Female Menopausal status Not specified Performance status Not specified Life expectancy Not specified Hematopoietic Not specified Hepatic Not specified Renal Not specified Other No active infection or inflammation in the breast under study No known allergy to eutectic mixture of local anesthetics (EMLA®) cream or lidocaine No severe illness Not unconscious No mental illness or handicap No nursing within the past 12 months Not pregnant PRIOR CONCURRENT THERAPY: Biologic therapy Not specified Chemotherapy Not specified Endocrine therapy Not specified Radiotherapy Not specified Surgery No prior breast implantation on side of proposed lavage No prior subareolar (e.g., papilloma resections, biopsies, or fine needle aspirations) or other surgery that may disrupt the ductal systems within 2 cm of the nipple Biopsies and fine-needle aspirations > 2 cm from the nipple are allowed

Sites / Locations

  • Royal Marsden - LondonRecruiting

Outcomes

Primary Outcome Measures

Correlation of cell yields and morphology in ductal lavage with duct endoscopy appearances and findings
Sensitivity and specificity of ductal lavage with or without ductoscopy in detecting atypical cells
Comparison of cell yields vs final surgical pathology of the operative specimens

Secondary Outcome Measures

Full Information

First Posted
May 14, 2004
Last Updated
August 23, 2013
Sponsor
Royal Marsden NHS Foundation Trust
search

1. Study Identification

Unique Protocol Identification Number
NCT00083018
Brief Title
Nipple Aspiration, Ductal Lavage, and Duct Endoscopy For Diagnostic Assessment in Women Undergoing Surgery for Breast Cancer
Official Title
Evaluation Of The Role Of Nipple Aspiration, Ductal Lavage And Duct Endoscopy At The Time Of Surgery In Patients With Breast Cancer
Study Type
Interventional

2. Study Status

Record Verification Date
December 2005
Overall Recruitment Status
Unknown status
Study Start Date
September 2003 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
Royal Marsden NHS Foundation Trust

4. Oversight

5. Study Description

Brief Summary
RATIONALE: Diagnostic procedures, such as nipple aspiration, ductal lavage, and breast duct endoscopy, may help doctors detect and assess breast cancer cells early and plan more effective treatment. PURPOSE: This phase II trial is studying how well nipple aspiration, ductal lavage, and duct endoscopy work in assessing cancer cells in women who are undergoing surgery for breast cancer.
Detailed Description
OBJECTIVES: Primary Correlate the cell yield and morphology findings from ductal lavage with duct endoscopy findings and surgical pathology findings in women with breast cancer. Determine the sensitivity and specificity of nipple aspiration, ductal lavage, and duct endoscopy in detecting established breast cancer in these patients. Secondary Compare the intraduct environment of cancer-involved ducts in the affected breast vs the ductal systems in the contralateral breast of these patients. Perform immunohistochemical analysis (including estrogen receptor, progesterone receptor, HER2-neu receptor, epidermal growth factor receptor, p53, and proliferation marker expression) for markers potentially associated with breast cancer in these patients. Determine potential molecular markers of malignancy by gene methylation, gene expression, and proteomics in these patients. Compare the biochemistry and protein analysis of the intraductal fluid vs serum analysis in these patients. OUTLINE: Patients undergo nipple aspiration, ductal lavage, and duct endoscopy under general anesthesia immediately before breast surgery. Fluid and tissue obtained are examined for tumor markers by immunohistochemistry. Candidate genes are analyzed by gene methylation, gene expression arrays, and proteomic profiling. Patients are followed at 24 hours and at 1 week. PROJECTED ACCRUAL: A total of 100 patients will be accrued for this study within 1 year.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Breast Cancer
Keywords
stage II breast cancer, stage IIIA breast cancer, stage IIIB breast cancer, stage IIIC breast cancer, stage IA breast cancer, stage IB breast cancer

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Phase 2
Enrollment
100 (Anticipated)

8. Arms, Groups, and Interventions

Intervention Type
Genetic
Intervention Name(s)
cytogenetic analysis
Intervention Type
Genetic
Intervention Name(s)
proteomic profiling
Intervention Type
Other
Intervention Name(s)
cytology specimen collection procedure
Intervention Type
Other
Intervention Name(s)
immunohistochemistry staining method
Intervention Type
Other
Intervention Name(s)
laboratory biomarker analysis
Intervention Type
Procedure
Intervention Name(s)
breast duct lavage
Primary Outcome Measure Information:
Title
Correlation of cell yields and morphology in ductal lavage with duct endoscopy appearances and findings
Title
Sensitivity and specificity of ductal lavage with or without ductoscopy in detecting atypical cells
Title
Comparison of cell yields vs final surgical pathology of the operative specimens

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
DISEASE CHARACTERISTICS: Diagnosis of breast cancer No metastatic disease No inflammatory breast cancer Hormone receptor status: Not specified PATIENT CHARACTERISTICS: Age 18 and over Sex Female Menopausal status Not specified Performance status Not specified Life expectancy Not specified Hematopoietic Not specified Hepatic Not specified Renal Not specified Other No active infection or inflammation in the breast under study No known allergy to eutectic mixture of local anesthetics (EMLA®) cream or lidocaine No severe illness Not unconscious No mental illness or handicap No nursing within the past 12 months Not pregnant PRIOR CONCURRENT THERAPY: Biologic therapy Not specified Chemotherapy Not specified Endocrine therapy Not specified Radiotherapy Not specified Surgery No prior breast implantation on side of proposed lavage No prior subareolar (e.g., papilloma resections, biopsies, or fine needle aspirations) or other surgery that may disrupt the ductal systems within 2 cm of the nipple Biopsies and fine-needle aspirations > 2 cm from the nipple are allowed
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Gerald Gui, MD, MS, FRCS(Edin), FRCS(Eng)
Organizational Affiliation
Royal Marsden NHS Foundation Trust
Official's Role
Study Chair
Facility Information:
Facility Name
Royal Marsden - London
City
London
State/Province
England
ZIP/Postal Code
SW3 6JJ
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Gerald Gui, MD, MS, FRCS(Edin), FRCS(Eng)
Phone
44-20-7808-2783
Email
gerald.gui@rmh.nhs.uk

12. IPD Sharing Statement

Learn more about this trial

Nipple Aspiration, Ductal Lavage, and Duct Endoscopy For Diagnostic Assessment in Women Undergoing Surgery for Breast Cancer

We'll reach out to this number within 24 hrs